Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials

L. Chiavaroli, D. Lee, A. Ahmed, A. Cheung, TA. Khan, S. Blanco, . Mejia, A. Mirrahimi, DJA. Jenkins, G. Livesey, TMS. Wolever, D. Rahelić, H. Kahleová, J. Salas-Salvadó, CWC. Kendall, JL. Sievenpiper

. 2021 ; 374 (-) : n1651. [pub] 20210804

Language English Country Great Britain

Document type Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review

Persistent link   https://www.medvik.cz/link/bmc21025161

OBJECTIVE: To inform the update of the European Association for the Study of Diabetes clinical practice guidelines for nutrition therapy. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, and the Cochrane Library searched up to 13 May 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials of three or more weeks investigating the effect of diets with low glycaemic index (GI)/glycaemic load (GL) in diabetes. OUTCOME AND MEASURES: The primary outcome was glycated haemoglobin (HbA1c). Secondary outcomes included other markers of glycaemic control (fasting glucose, fasting insulin); blood lipids (low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), non-HDL-C, apo B, triglycerides); adiposity (body weight, BMI (body mass index), waist circumference), blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)), and inflammation (C reactive protein (CRP)). DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted data and assessed risk of bias. Data were pooled by random effects models. GRADE (grading of recommendations assessment, development, and evaluation) was used to assess the certainty of evidence. RESULTS: 29 trial comparisons were identified in 1617 participants with type 1 and 2 diabetes who were predominantly middle aged, overweight, or obese with moderately controlled type 2 diabetes treated by hyperglycaemia drugs or insulin. Low GI/GL dietary patterns reduced HbA1c in comparison with higher GI/GL control diets (mean difference −0.31% (95% confidence interval −0.42 to −0.19%), P<0.001; substantial heterogeneity, I2=75%, P<0.001). Reductions occurred also in fasting glucose, LDL-C, non-HDL-C, apo B, triglycerides, body weight, BMI, systolic blood pressure (dose-response), and CRP (P<0.05), but not blood insulin, HDL-C, waist circumference, or diastolic blood pressure. A positive dose-response gradient was seen for the difference in GL and HbA1c and for absolute dietary GI and SBP (P<0.05). The certainty of evidence was high for the reduction in HbA1c and moderate for most secondary outcomes, with downgrades due mainly to imprecision. CONCLUSIONS: This synthesis suggests that low GI/GL dietary patterns result in small important improvements in established targets of glycaemic control, blood lipids, adiposity, blood pressure, and inflammation beyond concurrent treatment with hyperglycaemia drugs or insulin, predominantly in adults with moderately controlled type 1 and type 2 diabetes. The available evidence provides a good indication of the likely benefit in this population. STUDY REGISTRATION: ClinicalTrials.gov NCT04045938.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025161
003      
CZ-PrNML
005      
20211026134053.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmj.n1651 $2 doi
035    __
$a (PubMed)34348965
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Chiavaroli, Laura $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada
245    10
$a Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials / $c L. Chiavaroli, D. Lee, A. Ahmed, A. Cheung, TA. Khan, S. Blanco, . Mejia, A. Mirrahimi, DJA. Jenkins, G. Livesey, TMS. Wolever, D. Rahelić, H. Kahleová, J. Salas-Salvadó, CWC. Kendall, JL. Sievenpiper
520    9_
$a OBJECTIVE: To inform the update of the European Association for the Study of Diabetes clinical practice guidelines for nutrition therapy. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, and the Cochrane Library searched up to 13 May 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials of three or more weeks investigating the effect of diets with low glycaemic index (GI)/glycaemic load (GL) in diabetes. OUTCOME AND MEASURES: The primary outcome was glycated haemoglobin (HbA1c). Secondary outcomes included other markers of glycaemic control (fasting glucose, fasting insulin); blood lipids (low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), non-HDL-C, apo B, triglycerides); adiposity (body weight, BMI (body mass index), waist circumference), blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)), and inflammation (C reactive protein (CRP)). DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted data and assessed risk of bias. Data were pooled by random effects models. GRADE (grading of recommendations assessment, development, and evaluation) was used to assess the certainty of evidence. RESULTS: 29 trial comparisons were identified in 1617 participants with type 1 and 2 diabetes who were predominantly middle aged, overweight, or obese with moderately controlled type 2 diabetes treated by hyperglycaemia drugs or insulin. Low GI/GL dietary patterns reduced HbA1c in comparison with higher GI/GL control diets (mean difference −0.31% (95% confidence interval −0.42 to −0.19%), P<0.001; substantial heterogeneity, I2=75%, P<0.001). Reductions occurred also in fasting glucose, LDL-C, non-HDL-C, apo B, triglycerides, body weight, BMI, systolic blood pressure (dose-response), and CRP (P<0.05), but not blood insulin, HDL-C, waist circumference, or diastolic blood pressure. A positive dose-response gradient was seen for the difference in GL and HbA1c and for absolute dietary GI and SBP (P<0.05). The certainty of evidence was high for the reduction in HbA1c and moderate for most secondary outcomes, with downgrades due mainly to imprecision. CONCLUSIONS: This synthesis suggests that low GI/GL dietary patterns result in small important improvements in established targets of glycaemic control, blood lipids, adiposity, blood pressure, and inflammation beyond concurrent treatment with hyperglycaemia drugs or insulin, predominantly in adults with moderately controlled type 1 and type 2 diabetes. The available evidence provides a good indication of the likely benefit in this population. STUDY REGISTRATION: ClinicalTrials.gov NCT04045938.
650    _2
$a kardiometabolické riziko $7 D000083202
650    _2
$a diabetes mellitus 1. typu $x prevence a kontrola $7 D003922
650    _2
$a diabetes mellitus 2. typu $x prevence a kontrola $7 D003924
650    _2
$a diabetická dieta $7 D003927
650    _2
$a regulace glykemie $7 D000085002
650    12
$a glykemický index $7 D038321
650    12
$a glykemická nálož $7 D000067940
650    _2
$a lidé $7 D006801
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Lee, Danielle $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada
700    1_
$a Ahmed, Amna $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada
700    1_
$a Cheung, Annette $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada
700    1_
$a Khan, Tauseef A $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada
700    1_
$a Blanco, Sonia
700    1_
$a Mejia, $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada
700    1_
$a Mirrahimi, Arash $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada $u Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Department of Medical Imaging, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
700    1_
$a Jenkins, David J A $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada $u Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Division of Endocrinology and Metabolism, Department of Medicine, St Michael's Hospital, Toronto, ON, Canada $u Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada
700    1_
$a Livesey, Geoffrey $u Independent Nutrition Logic, Wymondham, UK
700    1_
$a Wolever, Thomas M S $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u INQUIS Clinical Research, Toronto, ON, Canada
700    1_
$a Rahelić, Dario $u Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia $u School of Medicine, University of Zagreb, Zagreb, Croatia $u School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
700    1_
$a Kahleová, Hana $u Institute for Clinical and Experimental Medicine, Diabetes Centre, Prague, Czech Republic $u Physicians Committee for Responsible Medicine, Washington, DC, USA
700    1_
$a Salas-Salvadó, Jordi $u Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, Reus, Spain $u Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari San Joan de Reus, Reus, Spain $u Consorcio CIBER, MP Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Kendall, Cyril W C $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada $u College of Pharmacy and Nutrition, University of Saskatchewan, SK, Canada
700    1_
$a Sievenpiper, John L $u Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada $u Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada $u Division of Endocrinology and Metabolism, Department of Medicine, St Michael's Hospital, Toronto, ON, Canada $u Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada
773    0_
$w MED00009350 $t BMJ (Clinical research ed.) $x 1756-1833 $g Roč. 374, č. - (2021), s. n1651
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34348965 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134059 $b ABA008
999    __
$a ok $b bmc $g 1714280 $s 1145668
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 374 $c - $d n1651 $e 20210804 $i 1756-1833 $m BMJ. British medical journal $n BMJ (Int Ed) $x MED00009350
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options